News

ZAS Industries Launches Advanced Wound Care Products from Pharmaplast.

ZAS Industries proudly announces the launch of a new range of premium wound care products from Pharmaplast, a global leader in wound care and cosmetic solutions. With a shared commitment to delivering quality and patient-focused innovations, this launch marks a significant step in advancing wound management standards in the local market. The newly introduced products […]

ZAS Industries Launches Advanced Wound Care Products from Pharmaplast. Read More »

ZAS Corporation & BIRDEM General Hospital Introduce Advanced Biosimilar Therapies in Rheumatology Care

ZAS Corporation is proud to collaborate with the Rheumatology Department of BIRDEM General Hospital to introduce three world-class biosimilar therapies from Celltrion Healthcare, Korea—Yuflyma® (adalimumab), Truxima® (rituximab), and Remsima® (infliximab).The initiative was formally marked at a recent CME event, where Dr. Sabrina Yesmin, Associate Professor & Head of the Rheumatology Department, shared her expert insights

ZAS Corporation & BIRDEM General Hospital Introduce Advanced Biosimilar Therapies in Rheumatology Care Read More »

ZAS Corporation Highlights Urovaxom® at OGSB International Scientific Conference 2025

ZAS Corporation Ltd. was honored to take part in the 33rd International Scientific Conference & 51st AGM of the Obstetrical and Gynaecological Society of Bangladesh (OGSB), held on 1–2 August 2025 at Pan Pacific Sonargaon, Dhaka. The event brought together eminent clinicians, researchers, and healthcare professionals from across the country and abroad.As part of our

ZAS Corporation Highlights Urovaxom® at OGSB International Scientific Conference 2025 Read More »

ZAS Corporation Hosts CME on Advancing Psoriasis Care with Adalimumab

ZAS Corporation’s Dermatology Division recently organized a Continuing Medical Education (CME) program at BIDSA, focusing on “The Role of Adalimumab in Psoriasis Management.” The session brought together leading dermatology experts to discuss updated clinical guidelines, recent research findings, and practical experiences in using adalimumab to manage moderate to severe psoriasis. Participants engaged in an interactive

ZAS Corporation Hosts CME on Advancing Psoriasis Care with Adalimumab Read More »

ZAS Corporation Empowers ICU Nurses with Noradrenaline Best Practices Training

ZAS Corporation recently organized a series of training sessions across multiple hospitals, engaging ICU nurses on the safe and effective use of noradrenaline in critical care settings. The program focused on practical guidance, updated protocols, and real-world application to support better patient outcomes. Through these interactive sessions, ZAS continues its commitment to enhancing clinical excellence

ZAS Corporation Empowers ICU Nurses with Noradrenaline Best Practices Training Read More »

ZAS Onco & MOSB Host Scientific Seminar on Recent Advances in Bevacizumab Therapy

ZAS Onco, a division of ZAS Corporation Ltd., in collaboration with the Medical Oncology Society of Bangladesh (MOSB), recently organized a scientific seminar titled “Recent Advances in Bevacizumab Therapy: Expanding the Horizon.” The event served as a valuable platform for oncologists and cancer care professionals to discuss the evolving clinical applications and therapeutic advancements of

ZAS Onco & MOSB Host Scientific Seminar on Recent Advances in Bevacizumab Therapy Read More »

ZAS Corporation Joins Aqvida GmbH in Celebrating 20 Years of Oncology Excellence in Germany

Hamburg & Dassow, Germany | 14–17 May 2025ZAS Corporation proudly participated in the 20th anniversary celebration of Aqvida GmbH, one of Europe’s most respected oncology pharmaceutical companies. The global event, held in Hamburg and Dassow, brought together healthcare leaders and partners from over 35 countries to commemorate two decades of innovation and excellence in cancer

ZAS Corporation Joins Aqvida GmbH in Celebrating 20 Years of Oncology Excellence in Germany Read More »

ZAS Corporation and Canyon Introduce Microwave Ablation for Fibroids for the First Time in Bangladesh

In a groundbreaking advancement for women’s healthcare in Bangladesh, ZAS Corporation, in collaboration with Canyon, has successfully launched Microwave Ablation for Fibroids for the very first time in the country. This innovative, minimally invasive procedure represents a new standard in fibroid treatment — offering faster recovery, reduced complications, and improved patient outcomes. The official launch

ZAS Corporation and Canyon Introduce Microwave Ablation for Fibroids for the First Time in Bangladesh Read More »

ZAS Ophthalmic Successfully Launches Timo-COMOD and Pollival with Leading Ophthalmologists

ZAS Ophthalmic, a concern of ZAS Group, proudly launched two innovative ophthalmic products — Timo-COMOD and Pollival — in the presence of distinguished ophthalmologists. This special event marked a significant milestone for ZAS Ophthalmic as it continues its commitment to bringing advanced, patient-friendly eye care solutions to Bangladesh. The launching program was held with the

ZAS Ophthalmic Successfully Launches Timo-COMOD and Pollival with Leading Ophthalmologists Read More »

Round Table Discussion on Preventing Recurrent RTIs in Children

Our Baby Care team recently hosted an engaging and insightful Round Table discussion with leading pediatricians, focusing on the prevention of recurrent respiratory tract infections (RTIs) in children. The session highlighted the role of Lyophilized Bacterial Lysates as a promising solution for boosting immunity and reducing the frequency of RTIs in young patients. The event

Round Table Discussion on Preventing Recurrent RTIs in Children Read More »

Scroll to Top